- Home
- CTMX vs BGB Comparison
CTMX vs BGB Comparison
Compare CTMX & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- BGB
- Stock Information
- Founded
- CTMX 2008
- BGB 2012
- Country
- CTMX United States
- BGB United States
- Employees
- CTMX N/A
- BGB N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- BGB Trusts Except Educational Religious and Charitable
- Sector
- CTMX Health Care
- BGB Finance
- Exchange
- CTMX Nasdaq
- BGB Nasdaq
- Market Cap
- CTMX 544.2M
- BGB 556.1M
- IPO Year
- CTMX 2015
- BGB N/A
- Fundamental
- Price
- CTMX $3.32
- BGB $11.96
- Analyst Decision
- CTMX Strong Buy
- BGB
- Analyst Count
- CTMX 5
- BGB 0
- Target Price
- CTMX $5.30
- BGB N/A
- AVG Volume (30 Days)
- CTMX 4.3M
- BGB 154.6K
- Earning Date
- CTMX 11-06-2025
- BGB 01-01-0001
- Dividend Yield
- CTMX N/A
- BGB 9.75%
- EPS Growth
- CTMX 263.20
- BGB N/A
- EPS
- CTMX 0.49
- BGB N/A
- Revenue
- CTMX $141,100,000.00
- BGB N/A
- Revenue This Year
- CTMX N/A
- BGB N/A
- Revenue Next Year
- CTMX N/A
- BGB N/A
- P/E Ratio
- CTMX $6.80
- BGB N/A
- Revenue Growth
- CTMX 18.01
- BGB N/A
- 52 Week Low
- CTMX $0.40
- BGB $10.40
- 52 Week High
- CTMX $3.49
- BGB $11.97
- Technical
- Relative Strength Index (RSI)
- CTMX 75.86
- BGB 27.51
- Support Level
- CTMX $3.11
- BGB $12.01
- Resistance Level
- CTMX $3.39
- BGB $12.24
- Average True Range (ATR)
- CTMX 0.24
- BGB 0.10
- MACD
- CTMX 0.10
- BGB -0.03
- Stochastic Oscillator
- CTMX 90.91
- BGB 2.62
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest
Blackstone Strategic Credit Fund is a closed-end term fund. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.